基于网络药理学的地榆升白片对白细胞减少症的作用机制研究  

Molecular Mechanism of Diyu Shengbai Tablets in Treatment of Leukopenia Based on Network Pharmacology

作　　者：刘金垒 但文超 何庆勇[1] 许博文[1,2] 曲艺 LIU Jin-lei;DAN Wen-chao;HE Qing-yong;XU Bo-wen;QU Yi(Guang′anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China2.Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]中国中医科学院广安门医院,北京100053 [2]北京中医药大学,北京100029

出　　处：《中国现代中药》2020年第9期1494-1501,共8页Modern Chinese Medicine

基　　金：北京市科技新星计划项目(Z181100006218035);中央本级重大增减支项目(2060302)。

摘　　要：目的:通过网络药理学方法探索地榆升白片治疗白细胞减少症的潜在作用机制。方法:采用中药系统药理学数据库和分析平台(TCMSP)、TCM-MESH数据库、ETCM平台筛选出地榆升白片的活性成分,利用Swiss ADME平台预测活性成分的潜在靶点。利用GeneCards、OMIM、Disgenet等数据库检索白细胞减少症相关靶点。利用Cytoscape 3.7.1构建“活性成分-靶点”网络,利用BioGenet分别构建药物与疾病靶点的蛋白质相互作用(PPI)网络,并提取交集网络以获得地榆升白片治疗白细胞减少症的关键靶点。通过Metascape对关键靶点进行GO和KEGG富集分析。结果:得到地榆升白片有效成分11个、药物靶点109个、白细胞减少症疾病靶点1204个,最终获得地榆升白片作用于白细胞减少症的关键靶点167个,KEGG通路48条。结论:地榆升白片治疗白细胞减少症主要成分为槲皮素、地榆皂苷、山柰酚,关键靶点为FUS、CUL5、NPM1、HNRNPA1,关键的生物学进程和通路包括细胞周期、DNA修复、细胞凋亡、河马通路等。Objective:To explore the potential pharmacological mechanism of Diyu Shengbai Tablets in the treatment of leukopenia based on the network pharmacological method.Methods:The active components of were screened through TCMSP,TCM-MESH database and ETCM.The potential targets of the active components were predicted according to the Swiss ADME.The related targets of leukopenia were screened through GeneCards,OMIM,Disgenet databases,etc.Cytoscape 3.7.1 was used to construct the network of″drug components-targets″,and the BioGenet database was used for protein-protein interaction network.The intersection network was extracted and the key targets of Diyu Shengbai Tablets in the treatment of leukopenia were obtained.Finally,GO and KEGG enrichment analysis of key targets were carried out by using Metascape.Results:There are 11 core active components of Diyu Shengbai Tablets for regulating leukopenia including quercetin,kaolinol,ziyuglycoside,etc.There are 109 ideal targets of Diyu Shengbai Tablets including FUS,CUL5,NPM1,etc.There are 1204 disease-related targets.Finally,there are 167 key targets and 48 KEGG pathways obtained.Conclusion:The main components of Diyu Shengbai Tablets for regulating leukopenia are quercetin,kaolinol,ziyuglycoside,etc.The key targets are FUS,CUL5,NPM1,HNRNPA1,etc.The key biological processes and pathways may include cell cycle,DNA repair,apoptosis,hippo pathway,etc.

关 键 词：地榆升白片 网络药理学 生物信息 分子机制 信号通路 

分 类 号：R285.5[医药卫生—中药学]